Skip to Content

Any cancer program can create a glossy annual report touting their program’s attributes. However, the American Society of Clinical Oncology, American College of Surgeons and the National Cancer Institute recognize that the challenge to cancer care quality is ensuring that patients are receiving the care known to be effective for their disease. The table below assesses adherence to and consideration of standard of care therapies for major cancers.

Cancer outcomes

How we compare* CHOMP CA US

Higher is better

Breast conservation surgery rate for women with stage 0, I, or II breast cancer. Based on multiple prospective randomized trials, breast conservation surgery is preferable because it provides survival rates equivalent to those of total mastectomy and axillary dissection
while preserving the breast.

Better 80% 61% 63%

Radiation therapy is considered or administered following any mastectomy within 1 year of diagnosis of breast cancer for women with > 4 positive regional lymph nodes. High level of evidence supports the measure, including multiple randomized control trials have shown a significant reduction in loco regional recurrence rates, disease-free survival rates, and even overall survival with this treatment.

Better 100% 83.5% 87.5%

Systemic chemotherapy is administered within 4 months before surgery or 6 months after surgery for Non-Small Cell Lung Cancer where cancer has spread to the pN1 and pN2 lymph nodes. Evidence from experimental studies, not randomized control trials supports this

Better 100% 86.4% 89.5%

*As compared to national benchmark

Montage Wellness Center